Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Synthorx
Biotech
Sanofi rethinks $2.5B IL-2 bet as phase 2 efficacy falls short
Sanofi has reported “lower than projected” efficacy data on its prospect and rethought its plans, stopping phase 2 trials and testing a new schedule.
Nick Paul Taylor
Oct 28, 2022 7:45am
Sanofi's engineered IL-2 clears safety hurdles in early data
Apr 12, 2021 8:20am
Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg
Apr 9, 2021 8:50am
Shawver takes the wheel at I-O biotech Silverback
Apr 22, 2020 8:00am
Sanofi inks $2.5B Synthorx takeover to gain IL-2 cancer drug
Dec 9, 2019 8:30am
